Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-C
Study sponsor: Ardelyx
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2031-07Estimated
Enrollment · participants150Estimated
Source updated2026-06-04Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.